|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||81.49 - 82.29|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.77%)|
|1y Target Est||N/A|
A possible reshaping of how some Medicare drugs are paid for has drug companies feeling sick. Health and Human Services Secretary Alex Azar's plan to consolidate at least some Part B prescription drugs under Part D could cost pharmaceutical companies real money since while there are no price negotiations under Part B, Part D includes discount, rebates and negotiating tools. Part B drugs are those that are administered in a doctor's office, clinic, hospital or someplace beyond the patient's home.
Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health. The above chart compares the segment-wise quarterly revenues for Eli Lilly since the first quarter of 2017. The US markets reported a 10% growth in revenues in the first quarter, driven by an 8% positive impact of prices and a 2% growth in volumes.
Eli Lilly’s (LLY) revenues surpassed Wall Street analysts’ estimates and reported a 9% growth to $5.7 billion for the first quarter. The above graph compares Eli Lilly’s quarterly revenues since the first quarter of 2017 and includes estimates for this year’s second quarter. Wall Street analysts estimate revenues of $6 billion for the second quarter, which would be a 3.7% growth compared to $5.8 billion in the second quarter of 2017.
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
The U.S. Food and Drug Administration on Thursday approved Amgen Inc's drug Aimovig for the prevention of migraine headaches in adults. The drug, given monthly by self injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, said Amgen spokeswoman Kristen Davis.
The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.
Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
During Teva’s (TEVA) 1Q18 earnings release on May 3, the company provided an update on the approval and launch of its anti-CGRP (calcitonin gene-related peptide) monoclonal antibody Fremanezumab, a preventive migraine treatment. The company stated that it now doesn’t expect to get FDA (U.S. Food and Drug Administration) approval for Fremanezumab in mid-June as it had earlier estimated. The reason that Teva doesn’t expect approval in June is that Celltrion, which is Teva’s API (active pharmaceutical ingredients) supplier of Fremanezumab, got a warning letter from the FDA in 2017.
The high-profile departure would be the latest in a string of exits of top investors in recent years from one of Silicon Valley's oldest and most successful venture firms.
In 1Q18, Valeant Pharmaceuticals’ (VRX) revenues witnessed an ~5.0% decline to reach $2.0 billion. Valeant Pharmaceuticals had an operating loss and net loss of ~$2.3 billion and ~$2.7 billion, respectively, in 1Q18. To learn more about its 1Q18 financial data, please read How Valeant Pharmaceuticals Performed in 1Q18.
Eli Lilly & Co. said Tuesday a phase 3 trial of galcanezumab for the treatment of episodic cluster headaches met its primary endpoint, and also achieved its secondary endpoint. Lilly said it is now working with regulatory agencies to determine the best path forward for galcanezumab. "Cluster headache can be difficult to evaluate in clinical studies, which has contributed to few available treatment options for cluster headache, often considered the most severe pain one can experience," said Christi Shaw, president of Lilly Bio-Medicines.
Eli Lilly and Co said on Tuesday that patients with episodic cluster headache attacks had reduced symptoms when treated with its experimental migraine drug galcanezumab compared to those treated with a placebo. Patients with episodic cluster headache treated with a 300 mg dose of galcanezumab experienced an average of 8.7 fewer headache attacks per week over a three-week period. Patients who participated in the trial had a baseline average of 17.5 cluster headache attacks per week.
Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors. The deal is Lilly's second in less than a week that aims to broaden its portfolio of lucrative cancer drugs. On Thursday, Lilly said it would buy Armo BioSciences Inc for about $1.6 billion.
Last week, Chairman, President and CEO of Eli Lilly and Company (LLY) Dave Ricks managed to merge powerful ideas about the context of health, global research initiatives and job competition in the state of Indiana into one talk. What Mr. Ricks ultimately proposed to do was take ideas that Lilly had learned in emerging markets – often referred to as developing countries – and apply those to neighborhoods in the U.S. with similar economic and health characteristics. This is especially true for diabetes, a group of diseases that affect how your body uses blood sugar, and is an important source of energy for cells.
WASHINGTON (AP) — President Donald Trump's long-promised plan to bring down drug prices would mostly spare the pharmaceutical industry he previously accused of "getting away with murder." Instead he focuses on private competition and more openness to reduce America's prescription pain.
Eli Lilly and Co. is buying ARMO BioSciences Inc. for $1.6 billion, the latest investment in the hot area of immunotherapy cancer treatments. Immunotherapy, or immune-cell therapy, describes a range of treatments that harness a patient’s own immune system to target cancer. Lilly said Thursday it reached a deal to buy ARMO, which had an initial public offering in January, for $50 a share in cash, a 68% premium to its closing price Wednesday.
In fiscal 1Q18, Teva Pharmaceutical Industries (TEVA) reported GAAP (generally accepted accounting principles) EPS of $1.03, whereas the non-GAAP EPS came in at $0.94. Teva’s gross profits in fiscal 1Q18 fell YoY by ~18% to $2.7 billion. The decline was mainly due to the weak performance in the North America region due to the lower Copaxone sales and pricing pressure in its generics business.
Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.